AI News NQ Analysis

Merck Completes Acquisition of JSR Life Sciences' Chromatography Business, Strengthening Protein A Technology and Expanding Downstream Portfolio

NQ Score 100/100

AI Summary (NQ-processed)

Merck has completed the acquisition of JSR Life Sciences' chromatography business, integrating advanced Protein A technology and Amsphere™ Protein A resins into its downstream process portfolio. This acquisition strengthens Merck's ability to support the efficient and scalable purification of monoclonal antibodies, helping customers improve productivity and accelerate access to critical therapeutics. Over 50 employees from the acquired Belgian chromatography unit will join Merck, enhancing its global technical support and application expertise in biopharmaceutical manufacturing.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What specific product line did Merck acquire from JSR Life Sciences in 2024?
A: Merck acquired the Amsphere™ Protein A resins and related chromatography technologies from JSR Life Sciences in 2024.
Q: How many employees from JSR Life Sciences' Belgian chromatography unit joined Merck after the acquisition?
A: Over 50 employees from JSR Life Sciences' Belgian chromatography unit joined Merck after the acquisition.
Q: Which technology does Merck's acquisition of JSR Life Sciences specifically enhance in its downstream portfolio?
A: The acquisition enhances Merck's Protein A technology within its downstream bioprocessing portfolio.
Q: What is the name of the resin product developed by JSR Life Sciences now integrated into Merck's offerings?
A: The resin product is called Amsphere™ Protein A, now part of Merck's chromatography portfolio.
Q: In what year did Merck complete the acquisition of JSR Life Sciences' chromatography business?
A: Merck completed the acquisition of JSR Life Sciences' chromatography business in 2024.